, IPO purchase proposal:
The company is the leading operator of private integrated medical services in Hong Kong, with comprehensive outpatient capabilities covering general medical services, specialist medical services and dental services. According to the Euromonitor report, on August 31, 2015, the company ranked first among private medical service operators in Hong Kong (notes) in terms of the number of medical centers. As at the latest practicable date, the Group has been providing medical services to the people of Hong Kong since 1997. Through the company's network of medical centres in Hong Kong, the company earns revenue from a growing market that generates strong demand for its services. As at the latest practicable date, the company operates 66 medical centres in 18 districts of Hong Kong, most of which are located in or near MTR stations, adjacent to public transport hubs, shopping malls or residential areas. In the company's medical center, the company has 115 service points to provide medical services covering a wide range of subjects, including 57 general practice service points, 45 specialist medical service points and 13 dental service points. The company's integrated medical services cover 11 areas, namely surgery, orthopaedics, ophthalmology, otorhinolaryngology, paediatrics, obstetrics and gynaecology, gastroenterology and liver, respiratory, cardiology, pediatric surgery and dermatology, as well as the company's general medical services and dental services, making the company a leader in integrated medical services operators. In fiscal year 2015, the revenue generated by individual customers and corporate customers accounted for approximately 79.3% and 20.7% of the company's total revenue for that financial year, respectively. In addition, as at September 30, 2015, the company had approximately 1.73 million patients and approximately 1.23 million patient visits in fiscal year 2015. The company's outstanding market position is attributed to the company's experienced and stable professional team. The company's general medical services, specialist medical services, and dental services accounted for 75.6%, 21.2% and 3.2%, respectively.
The company's total revenue increased from approximately HK $333.9 million in fiscal year 2013 to approximately HK $365.2 in fiscal year 2014 and to approximately HK $429.5 in fiscal year 2015, representing a compound annual growth rate of approximately 13.4%. The company's total revenue increased by approximately 31.5% from approximately HK $84.3 million for the three months ended September 30, 2014 to approximately HK $110.8 for the three months ended September 30, 2015.
The guidance price per share is HK $1.32-HK $1.51, which is equivalent to about 15 times the price of PE13 -. The valuation of the company is reasonable and it is recommended to actively subscribe.